Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).

@article{Frasci2000WeeklyDP,
  title={Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).},
  author={Giuseppe Frasci and Pasquale Comella and G D'aiuto and Renato Thomas and Immacolata Capasso and Massimo Elmo and Gerardo Botti and Giuseppina Rosa Cortino and Liliana Lapenta and Vincenzo de Rosa and Paolo Vallone and Angelica Petrillo and Giuseppe Comella},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2000},
  volume={11 3},
  pages={367-71}
}
PURPOSE The objective of this study was to determine the docetaxel MTD when combined with gemcitabine or vinorelbine in advanced breast cancer patients who had received previous anthracycline-based chemotherapy for advanced disease. PATIENTS AND METHODS Advanced breast cancer patients aged between 18 and 70 with ECOG PS 0-2 who had not responded to, or… CONTINUE READING